| All sarcoidosis patients# | Sarcoidosis patients treated with immunosuppressive agents¶ | |||||||||||||
| 0 to <3 months | 3 months to <3 years | 3-10 years | >10 years | Overall | 3–10 years | >10 years | ||||||||
| All+ | 149 | 9.1 (7.7–10.7) | 243 | 1.5 (1.3–1.7) | 419 | 1.2 (1.1–1.3) | 492 | 1.1 (1.0–1.2) | 1303 | 1.3 (1.3–1.4) | 74 | 1.2 (0.9–1.5) | 27 | 1.3 (0.9–2.0) |
| Tonsils | 20 | 63.8 (39.0–98.6) | 11 | 3.5 (1.7–6.2) | 13 | 2.1 (1.1–3.6) | 7 | 1.3 (0.5–2.6) | 51 | 3.4 (2.5–4.4) | 0 | 0 | ||
| Stomach | 0 | 1 | 0.4 (0.00–2.1) | 6 | 1.1 (0.4–2.5) | 7 | 1.1 (0.4–2.2) | 14 | 1.0 (0.5–1.6) | 1 | 1.2 (0.0–6.8) | 0 | ||
| Colon | 6 | 5.8 (2.1–12.6) | 11 | 1.1 (0.5–1.9) | 37 | 1.7 (1.2–2.4) | 28 | 1.0 (0.7–1.4) | 83 | 1.4 (1.1–1.7) | 6 | 1.6 (0.6–3.6) | 2 | 1.6 (0.2–5.9) |
| Rectum | 4 | 7.1 (1.9–18.1) | 4 | 0.7 (0.2–1.8) | 13 | 1.1 (0.6–1.9) | 19 | 1.2 (0.7–1.9) | 40 | 1.2 (0.9–1.6) | 2 | 1.0 (0.1–3.5) | 1 | 1.5 (0.0–8.2) |
| Pancreas | 3 | 8.4 (1.7–24.6) | 1 | 0.3 (0.0–1.6) | 8 | 1.1 (0.5–2.2) | 10 | 1.0 (0.5–1.9) | 22 | 1.1 (0.7–1.6) | 1 | 0.8 (0.0–4.4) | 0 | |
| Gall bladder/biliary tract | 0 | 1 | 1.2 (0.0–6.4) | 4 | 2.4 (0.6–6.0) | 6 | 2.9 (1.1–6.3) | 11 | 2.3 (1.2–4.2) | 0 | 1 | 11.1 (0.3–61.7) | ||
| Lungs | 32 | 18.7 (12.8–26.3) | 25 | 1.5 (0.9–2.1) | 31 | 0.9 (0.6–1.3) | 26 | 0.6 (0.4–0.8) | 114 | 1.1 (0.9–1.4) | 11 | 1.8 (0.9–3.2) | 2 | 1.0 (0.1–3.6) |
| Breast | 3 | 1.4 (0.3–4.1) | 19 | 0.9 (0.5–1.3) | 42 | 0.9 (0.6–1.2) | 54 | 1.0 (0.7–1.3) | 118 | 0.9 (0.8–1.1) | 6 | 0.8 (0.3–1.7) | 2 | 0.8 (0.1–3.0) |
| Malignant melanoma | 2 | 3.2 (0.4–11.4) | 4 | 0.6 (0.2–1.5) | 10 | 0.7 (0.3–1.3) | 15 | 0.9 (0.5–1.5) | 30 | 0.8 (0.5–1.2) | 3 | 1.1 (0.2–3.3) | 2 | 2.5 (0.3–8.9) |
| Basal cell carcinoma | 5 | 1.9 (0.6–4.4) | 53 | 1.9 (1.4–2.5) | 86 | 1.4 (1.1–1.8) | 107 | 1.2 (1.0–1.5) | 251 | 1.4 (1.2–1.6) | 15 | 1.2 (0.7–2.0) | 5 | 1.2 (0.4–2.7) |
| Squamous cell skin cancer | 1 | 2.6 (0.1–14.3) | 12 | 3.0 (1.6–5.3) | 20 | 2.4 (1.5–3.7) | 42 | 3.2 (2.3–4.3) | 75 | 2.9 (2.3–3.6) | 5 | 2.6 (0.9–6.2) | 1 | 1.5 (0.0–8.2) |
| Cervix uteri | 1 | 3.3 (0.1–18.2) | 4 | 1.3 (0.3–3.3) | 6 | 1.0 (0.4–2.2) | 5 | 1.1 (0.3–2.5) | 16 | 1.1 (0.7–1.9) | 1 | 1.3 (0.0–7.4) | 0 | |
| Uterus | 1 | 2.6 (0.1–14.7) | 5 | 1.3 (0.4–3.0) | 7 | 0.9 (0.4–1.9) | 11 | 1.2 (0.6–2.2) | 24 | 1.1 (0.7–1.7) | 1 | 0.9 (0.0–4.9) | 1 | 2.7 (0.1–14.9) |
| Ovary | 1 | 3.1 (0.1–17.2) | 2 | 0.6(0.1–2.2) | 7 | 1.1 (0.4–2.2) | 10 | 1.4 (0.7–2.6) | 20 | 1.2 (0.7–1.8) | 1 | 1.1 (0.0–6.2) | 0 | |
| Prostate | 5 | 5.2 (1.7–12.0) | 10 | 1.0 (0.5–1.9) | 21 | 1.7 (0.7–1.6) | 41 | 1.2 (0.8–1.6) | 77 | 1.2 (0.9–1.5) | 5 | 1.0 (0.3–2.3) | 4 | 2.3 (0.6–6.0) |
| Testes | 0 | 1 | 0.4 (0.0–2.1) | 7 | 1.5 (0.6–3.1) | 4 | 1.3 (0.3–3.3) | 12 | 1.1 (0.6–2.0) | 2 | 2.7 (0.3–9.7) | 0 | ||
| Kidney | 3 | 11.1 (2.3–32.4) | 4 | 1.5 (0.4–3.8) | 6 | 1.1 (0.4–2.3) | 9 | 1.2 (0.5–2.3) | 22 | 1.4 (0.8–2.1) | 1 | 1.0 (0.0–5.4) | 1 | 3.0 (0.1–16.5) |
| Bladder | 2 | 5.9 (0.7–21.4) | 3 | 0.9 (0.2–2.6) | 7 | 1.1 (0.4–2.2) | 4 | 0.5 (0.1–1.1) | 16 | 0.8 (0.5–1.4) | 2 | 1.7 (0.2–6.2) | 1 | 2.7 (0.1–14.9) |
| Brain | 6 | 13.1 (4.8–28.5) | 16 | 3.4 (1.9–5.5) | 12 | 1.3 (0.7–2.2) | 6 | 0.6 (0.2–1.2) | 40 | 1.6 (1.1–2.1) | 2 | 1.2 (0.1–4.4) | 0 | |
| Hodgkin lymphoma | 9 | 107 (49.0–203) | 6 | 7.2 (2.6–15.7) | 4 | 2.7 (0.7–6.9) | 0 | 19 | 5.3 (3.2–8.2) | 2 | 8.8 (1.1–31.8) | 0 | ||
| Non-Hodgkin lymphoma | 23 | 57.1 (36.2–85.7) | 21 | 5.1 (3.2–7.8) | 18 | 2.1 (1.2–3.3) | 18 | 1.6 (1.0–2.6) | 80 | 3.3 (2.6–4.1) | 2 | 1.3 (0.2–4.7) | 1 | 2.0 (0.1–11.3) |
| Myeloid leukaemia | 3 | 21.5 (4.4–62.8) | 5 | 3.6 (1.2–8.3) | 4 | 1.4 (0.4–3.7) | 2 | 0.6 (0.1–2.3) | 14 | 1.9 (1.0–3.1) | 0 | 0 | ||
| Multiple myeloma | 5 | 37.4 (12.1–87.1) | 4 | 3.0 (0.8–7.6) | 6 | 2.2 (0.8–4.7) | 5 | 1.4 (0.4–3.2) | 20 | 2.5 (1.5–3.9) | 1 | 2.1 (0.1–11.7) | 0 | |
Data are presented as observed number or SIR (95% CI). #: n = 12 890; ¶: n = 3115; +: the site specific numbers do not add up to the total number because not all cancer sites are presented.